Dosimetric properties of a newly developed thermoluminescent sheet-type dosimeter for clinical proton beams.

PURPOSE: This study aimed to evaluate the dosimetric properties of a newly developed thermoluminescent sheet-type dosimeter (TLD-sheet) for clinical proton beams. MATERIALS AND METHODS: The TLD-sheet is composed mainly of manganese doped lithium triborate, with a physical size and thickness of 150 mm × 150 mm and 0.15 mm respectively. It is flexible and can be cut freely for usage. The TLD-sheet has an effective atomic number of 7.3 and tissue-equivalent properties. We tested the reproducibility, fading effect, dose linearity, homogeneity, energy dependence, and water equivalent thickness (WET) of the TLD-sheet for clinical proton beams. We conducted tests with both unmodulated and modulated proton beams at energies of 150 and 210 MeV. RESULTS: The measurement reproducibility was within 4%, which included the inhomogeneity of the TLD-sheet. The fading rates were approximately 20% and 30% after 2 and 7 days respectively. The TLD-sheet showed notable energy dependence in the Bragg peak and distal end of the spread-out Bragg peak regions. However, the dose-response characteristics of the TLD-sheet remained linear up to a physical dose of 10 Gy in this study. This linearity was highly superior to those of commonly used radiochromic film. The thin WET of the TLD-sheet had little effect on the range. CONCLUSION: Although notable energy dependences were observed in Bragg peak region, the response characteristics examined in this study, such as reproducibility, fading effects, dose linearity, dose homogeneity and WET, showed that the TLD-sheet can be a useful and effective dosimetry tool. With its flexible and reusable characteristics, it may also be an excellent in vivo skin dosimetry tool for proton therapy.

Assessment of skin dose in breast cancer radiotherapy: on-phantom measurement and Monte Carlo simulation.

AIM: The main purpose of the present study is assessment of skin dose in breast cancer radiotherapy. BACKGROUND: Accurate assessment of skin dose in radiotherapy can provide useful information for clinical considerations. MATERIALS AND METHODS: A RANDO phantom was irradiated using a 6 MV Siemens Primus linac with medial and tangential radiotherapy fields for simulating breast cancer treatment. Dosimetry was also performed on various positions across the fields using an EBT3 radiochromic film. Similar conditions of measurement on the RANDO phantom including field size, irradiation angle, number of fields, etc. were subsequently simulated via the Monte Carlo N-Particle Transport code (MCNP). Ultimately, dose values for corresponding points from both methods were compared. RESULTS: Considering dosimetry using radiochromic films on the RANDO phantom, there were points having underdose and overdose based on the prescribed dose and skin tolerance levels. In this respect, 81.25% and 18.75% of the points had underdose and overdose, respectively. In some cases, several differences were observed between the measurement and the MCNP simulation results associated with skin dose. CONCLUSION: Based on the results of the points which had underdose, it was suggested that a bolus should be used for the given points. With regard to overdose points, it was advocated to consider skin tolerance dose in treatment planning. Differences between the measurement and the MCNP simulation results might be due to voxel size of tally cells in simulations, effect of beam's angle of incidence, validation time of linac's head, lack of electronic equilibrium in the build-up region, as well as MCNP tally type.

Dose Agreement Analysis of Treatment Planning System-Calculated Doses and Markus Chamber-Measured Doses in the Near-Surface Region for Breast Cancer Patients' Conformal Treatment Plans.

Background: Surface/skin dose measurement is one of the most challenging tasks for clinical dosimetry in radiotherapy and comparison with almost all the commercially available treatment planning systems (TPSs) brings a significant variation with the measured dose. Aims and Objectives: In the current study, doses calculated from the TPS in the near-surface region for conformal plans (both three-dimensional conformal radiotherapy [3DCRT] and intensity-modulated radiotherapy [IMRT]) of 35 breast cancer patients were evaluated and compared with the doses measured with Markus chamber. Materials and Methods: The computed tomography (CT) images of a solid water slab phantom with a Markus chamber (at different depths ranging from 1 mm to 5 mm from the surface) were taken and imported into the TPS. All the conformal treatment plans made in TPS were executed on a linear accelerator and dose agreements between TPS calculated and chamber measured doses were analysed. Results: Results showed that this TPS underestimated the calculated doses in the superficial region by up to 26% and 21%, respectively, with respect to mean and maximum dose values obtained within the effective volume of the chamber used. Conclusion: The uncertainty of doses in the superficial region should be kept in mind when evaluating treatment plans for superficial tumours in TPS.

Quantitative Effect of Bolus on Skin Dose in Postmastectomy Radiation Therapy.

BACKGROUND: In postmastectomy radiation therapy (PMRT), some centres prescribe the use of a tissue-equivalent bolus to the skin to reduce the risk of chest wall recurrence. The addition of bolus causes an increase in the skin dose, which may lead to increased risk of radiodermatitis. Radiodermatitis can decrease patients' overall quality of life, bringing into question the benefit of using the bolus. The purpose of this retrospective chart review was to quantify the increase in skin dose associated with the use of bolus in the PMRT setting. MATERIALS AND METHODS: We evaluated 70 patients who underwent PMRT at our institution during 2012-2018. Two similar treatment plans were generated for each patient: one with bolus and one without. Skin dose-volume histogram values were evaluated, and statistical analysis was performed using MATLAB R2015b. RESULTS: There was no significant difference in the maximum skin dose within a depth of 5 mm for bolus versus nonbolus plans (P = 0.4). However, within a depth of 3 mm, bolus plans had a maximum skin dose 7% ± 2.5% higher than the nonbolus plans (P < .00001). Mean skin dose within depths of 3 and 5 mm were both significantly higher (P < .00001) for bolus plans. The photon beam energy and chest wall separation showed minimal or no effect on skin dose. CONCLUSION: Given the differing opinions in the literature regarding the role for bolus in PMRT, there is still uncertainty of the optimal treatment method. This retrospective study demonstrates a 20%-30% reduction in mean skin dose when bolus is not used.

Subcutaneous spacer injection to reduce skin toxicity in breast brachytherapy: A pilot study on mastectomy specimens.

PURPOSE: Accelerated partial breast irradiation is a treatment option for selected patients with early-stage breast cancer. Some accelerated partial breast irradiation techniques lead to skin toxicity with the skin dose as a main risk factor. Biodegradable spacers are effective and safe in prostate brachytherapy to protect the rectum. We hypothesize that a subcutaneous spacer injection reduces the skin dose in breast brachytherapy. METHODS AND MATERIALS: Ultrasound-guided spacer injections, either hyaluronic acid (HA) or iodined polyethylene glycol (PEG), were performed on fresh mastectomy specimens. Success was defined as a spacer thickness of ≥5 mm in the high-dose skin area. Usability was scored using the system usability scale. Pre and postinjection CT scans were used to generate low-dose-rate seed brachytherapy treatment plans after defining a clinical target volume. Maximum dose to small skin volumes (D0.2cc) and existence of hotspots (isodose ≥90% on 1 cm2 of skin) were calculated as skin toxicity indicators. RESULTS: We collected 22 mastectomy specimens; half had HA and half had PEG injection. Intervention success was 100% for HA and 90.9% for PEG (p = NS). Hydrodissection was feasible in 81.8% with HA and 63.6% with PEG. Median system usability scale score was 97.5 for HA and 82.5 for PEG (p < 0.001). Mean D0.2cc was 80.8 Gy without spacer and 53.7 Gy with spacer (p < 0.001). Skin hotspots were present in 40.9% without spacer but none with spacer (p < 0.001). CONCLUSIONS: A spacer injection in mastectomy specimens is feasible. An extra 5 mm space is always achieved, thereby potentially reducing the skin dose dramatically in low-dose-rate seed breast brachytherapy.

Peri-anal surface dose in anal canal VMAT radiotherapy.

INTRODUCTION: Skin bolus may routinely be used in the perineum to build up the surface dose in the treatment of anal cancer (ACC); this may contribute to significant acute skin toxicity. Skin bolus may not be needed with the introduction of modern radiotherapy techniques if these planning techniques would achieve adequate surface dose. Our study is to ascertain if appropriate skin dose can be achieved without the use of bolus when VMAT is used in the treatment of ACC. METHODS: The study includes 10 ACC patients treated with VMAT radiotherapy. Optically stimulated luminescence dosimeters (OSLD) are used to evaluate whether the calculated dose for the VMAT planning technique (VMAT-PT) accurately predicted the dose delivered to peri-anal target region without bolus. The OSLD recorded the dose at the anal verge or at the lower most extent of the tumour for each patient over two fractions. The OSLD was read after each of the two fractions, and the average value was reported. The mean dose over a volume centred on the anal marker was calculated in the treatment planning system (TPS). RESULTS: The mean TPS-calculated dose was 186.1 cGy. The mean of the OSLD-measured doses was 205.7 cGy for a single fraction. The mean of the measured doses was 10.6% higher than the mean of the calculated doses. CONCLUSIONS: The calculated dose for the VMAT-PT consistently under-predicted the dose delivered to the peri-anal target region without bolus. Routine use of skin bolus could be avoided with VMAT-PT when the patient is treated in a supine position.

Dosimetric effects of brass mesh bolus on skin dose and dose at depth for postmastectomy chest wall irradiation.

PURPOSE: To investigate the feasibility of using the brass mesh bolus as an alternative to tissue- equivalent bolus for post mastectomy chest wall cancer by characterizing the dosimetric effects of the 2-mm fine brass bolus on both the skin dose, the dose at depth and spatial distribution. MATERIALS AND METHODS: Surface dose and percent depth dose data were acquired for a 6 MV photon beam in a solid water phantom using MOSkin™, Gafchromic EBT3 film and an Advanced Markus ionization chamber. Data were acquired for the case of: no bolus, Face-up bass bolus, Face-down brass bolus, double brass bolus, 0.5 cm and 1.0 cm of Superflab TE bolus. The exit doses were also measured via MOSkin™ dosimeter and Markus ionization chamber. Gafchromic EBT3 film strips were used to plot dose profile at surface and 10 cm depth for Face-up brass, Face-down brass, double brass, 0.5 cm and 1.0 cm of Superflab TE bolus. RESULTS: The surface dose measured via MOSkin™ dosimeter increased from 19.2 ±â€¯1.0% to 63.1 ±â€¯2.1% under Face-up brass discs, 51.2 ±â€¯1.2% under Face-up brass spaces, 61.5 ±â€¯0.5% under Face-down brass discs, and 41.3 ±â€¯2.1% under Face-down brass spaces. The percentage difference in the dose measured under brass discs between Face-up versus Face-down was less than 2% for entrance dose and 10% for exit dose, whereas the percentage difference under brass spaces was approximately 3% for entrance dose and about 5% for the exit dose. Gafchromic EBT3 film strip measurements show that the mesh bolus produced ripple beam profiles due to the mesh brass construction. CONCLUSIONS: Brass bolus does not significantly change dose at depth (less than 0.5%), and the surface dose is increased similar to TE bolus. Considering this, brass mesh may be used as a substitute for TE bolus to increase superficial dose for chest wall tangent plans.

Development of a silicon diode detector for skin dosimetry in radiotherapy.

PURPOSE: The aim of in vivo skin dosimetry was to measure the absorbed dose to the skin during radiotherapy, when treatment planning calculations cannot be relied on. It is of particularly importance in hypo-fractionated stereotactic modalities, where excessive dose can lead to severe skin toxicity. Currently, commercial diodes for such applications are with water equivalent depths ranging from 0.5 to 0.8 mm. In this study, we investigate a new detector for skin dosimetry based on a silicon epitaxial diode, referred to as the skin diode. METHOD: The skin diode is manufactured on a thin epitaxial layer and packaged using the "drop-in" technology. It was characterized in terms of percentage depth dose, dose linearity, and dose rate dependence, and benchmarked against the Attix ionization chamber. The response of the skin diode in the build-up region of the percentage depth dose (PDD) curve of a 6 MV clinical photon beam was investigated. Geant4 radiation transport simulations were used to model the PDD in order to estimate the water equivalent measurement depth (WED) of the skin diode. Measured output factors using the skin diode were compared with the MOSkin detector and EBT3 film at 10 cm depth and at surface at isocenter of a water equivalent phantom. The intrinsic angular response of the skin diode was also quantified in charge particle equilibrium conditions (CPE) and at the surface of a solid water phantom. Finally, the radiation hardness of the skin diode up to an accumulated dose of 80 kGy using photons from a Co-60 gamma source was evaluated. RESULTS: The PDD curve measured with the skin diode was within 0.5% agreement of the equivalent Geant4 simulated curve. When placed at the phantom surface, the WED of the skin diode was estimated to be 0.075 ± 0.005 mm from Geant4 simulations and was confirmed using the response of a corrected Attix ionization chamber placed at water equivalent depth of 0.075 mm, with the measurement agreement to within 0.3%. The output factor measurements at 10 cm depth were within 2% of those measured with film and the MOSkin detector down to a field size of 2 × 2 cm2 . The dose-response for all detector samples was linear and with a repeatability within 0.2%. The skin diode intrinsic angular response showed a maximum deviation of 8% at 90 degrees and from 0 to 60 degree is less than 5%. The radiation sensitivity reduced by 25% after an accumulated dose of 20 kGy but after was found to stabilize. At 60 kGy total accumulated dose the response was within 2% of that measured at 20 kGy total accumulated dose. CONCLUSIONS: This work characterizes an innovative detector for in vivo and real-time skin dose measurements that is based on an epitaxial silicon diode combined with the Centre for Medical Radiation Physics (CMRP) "drop-in" packaging technology. The skin diode proved to have a water equivalent depth of measurement of 0.075 ± 0.005 mm and the ability to measure doses accurately relative to reference detectors.